Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Rae Cook/Axios

The Biden administration is expected to soon recommend booster doses of the COVID-19 vaccine for everyone, but that decision fails fundamental ethics tests, according to interviews with physicians and medical ethicists.

Why it matters: There is still a global shortage of vaccines. Even amid concerns of the spreading Delta variant, experts say it's difficult to justify a third dose for relatively healthy people in the U.S. when many others haven't gotten their first.

Driving the news: The booster shots would likely be administered around eight months after someone received their two mRNA vaccine doses from Pfizer or Moderna, or after their single Johnson & Johnson shot, according to initial reports.

  • An independent CDC panel and the FDA have not signed off on this plan yet.
  • This possible plan comes a week after the CDC and FDA formally recommended the nation's 9 million immunocompromised people get a third dose of the Pfizer or Moderna vaccine.
  • Data have indicated for months that the immunocompromised, especially organ transplant patients, were less protected from the two-shot course.
  • A third dose for the immunocompromised is reasonable, ethicists say, because three doses should have been their default regimen, and it will give a boost in protection to a group that is more likely to end up in the hospital from COVID-19.

Yes, but: "Once you get to anybody who wants to get a third dose, then I think other people in other countries start to have a rightful basis for complaint," said Govind Persad, a health policy and ethics professor at the University of Denver.

  • The vaccines appear to be less effective as time goes on, but there's no rigorous data quantifying that yet.
  • The vaccines still prevent almost all instances of death and hospitalization from severe disease.
  • The risk of vaccinated people with normal immune systems passing the Delta variant on to other vaccinated people also appears very low.
  • Meanwhile, the coronavirus is raging in low-vaccinated places like Botswana, Cuba and Iran, which "translates into disparities in mortality rates from COVID-19," ethicists wrote in JAMA last week.

"We have people in sizable numbers who have zero protection," said Ruth Faden, a bioethicist at Johns Hopkins University and member of the World Health Organization's panel that advised against boosters except for high-risk people. "The global ethics case is clear."

Reality check: The U.S. has bought enough vaccine doses to immunize everyone, and that stockpile has come at the expense of other countries.

  • Experts agree no vaccine should be wasted or allowed to expire, and it also may not be logistically feasible for the U.S. to ship some of its surplus doses elsewhere.
  • But variants have become a top concern precisely because of the maldistribution of vaccines.
  • "This virus has proven what most pathogens do: They mutate," said Doug Diekema, a bioethicist and physician at Seattle Children’s Hospital. "The best way to stop that is to stop transmission, and to do that, you have to get as many people vaccinated as possible."

The bottom line: "The Delta variant didn't come from nowhere," Faden said. "To have a better chance of containing this pandemic, we have a self-interested reason in seeing vaccination coverage go up in people outside of our country."

Go deeper

Updated Nov 27, 2021 - Health

COVID-19 Omicron variant cases identified in Europe, U.K.

People wearing masks walk in London on Nov. 25. Photo: Li Ying/Xinhua via Getty Images

Health officials in the United Kingdom, Italy and Germany announced on Saturday that they've detected the first known cases of the new COVID-19 Omicron variant.

Why it matters: The discoveries come as the world scrambles to respond to concerns over the new variant, discovered in South Africa earlier this week.

Nov 27, 2021 - World

South Africa says it's being "punished" for detecting new COVID variant

South African Foreign Minister Naledi Pandor addresses the 76th session of the U.N. General Assembly on Sept. 22 in New York City. Photo: Eduardo Munoz - Pool/Getty Images

South Africa said Saturday it's being "punished" for detecting the new Omicron coronavirus variant as more countries rush to enact travel bans and restrictions.

Driving the news: The U.S. imposed air travel restrictions from eight countries Friday in response to the Omicron variant. Countries in Europe and Asia have also implemented their own travel restrictions in response to Omicron.

Tina Reed, author of Vitals
Updated Nov 26, 2021 - Health

COVID vaccines of the future might not be shots

Illustration: Aïda Amer/Axios

As vaccine makers pursue the next generation of COVID-19 vaccines, some are working to develop products that wouldn't require a shot.

Why it matters: Delivering a vaccine through a pill or a nasal spray could make them much easier to administer, especially in places where distribution is challenging — or even for people who just don't like needles.